WallStreetZenWallStreetZen

NASDAQ: CRVO
Cervomed Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Be the first to know when Wall Street analysts revise their CRVO stock forecasts and price targets.

Forecast return on equity

Is CRVO forecast to generate an efficient return?
Company
N/A
Industry
0.6%
Market
28.78%

Forecast return on assets

Is CRVO forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.1%

CRVO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CRVO$4.63N/AN/A
PCSA$0.26$3.50+1,246.15%Buy
CFRX$0.58$3.00+417.24%Strong Buy
TCON$0.20$3.00+1,422.84%Strong Buy
XCUR$0.78N/AN/A
View Top Biotech Stocks

Cervomed Stock Forecast FAQ

What is CRVO's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: CRVO) forecast ROE is N/A, which is considered weak.

If you're new to stock investing, here's how to buy Cervomed stock.

What is CRVO's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: CRVO) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.1%.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.